Ficus

by | Mar 19, 2018 | Ficus

How Can We Help?
You are here:
< Back

CX157 (proposed trade name TriRima, formerly Tyrima) is a selective and reversible inhibitor of MAO-A (RIMA).[1] As of 2007 it was in phase II clinical trials for the treatment of depression.[2] In 2013, work on the drug was terminated.[1]

References

  1. ^ Fielding R, Mielach F, Free J, Pande A (2007). Pharmacokinetics and oral bioavailability of CX157, a reversible selective MAO-A inhibitor, in primates (PDF). 2007 AAPS Annual Meeting & Exposition. Archived from the original (PDF) on 2011-05-26. Retrieved 2009-06-14.
  2. ^ Clinical trial number NCT00739908} for "A Study of CX157 (TriRima) for the Treatment of Depression (CX157-200)" at ClinicalTrials.gov



Categories
Table of Contents